[Munich, ] A team from GÖRG Partnerschaft von Rechtsanwälten mbB, led by two partners, Dr Bernt Paudtke (corporate advice) and Dr Oliver Spieker (advice on IP topics), has provided advice to Rentschler Biotechnologie GmbH in connection with its transaction with Leukocare AG.
As a result of the cooperation between the companies, Rentschler has acquired 10% of the shares in Leukocare and its director, Dr Frank Mathias, has joined Leukocare’s supervisory board.
Founded in 1927, Rentschler is a privately owned and independent company with its headquarters in Laupheim. It is a leading worldwide full-service service provider for biopharmaceuticals. In this sector, Rentschler provides services to its customers in relation to process development, cGMP manufacturing, filling of biopharmaceuticals and the creation of approval strategies for their products. Rentschler assumes the role of outsourcing partner from the beginning of product development up until a biopharmaceutical product is ready for market. Thanks to its focus on innovations, Rentschler is always on the cutting edge of technologies and ready to provide the basis for biotechnological pharmaceuticals.
Through its alliance with Leukocare, Rentschler acquires a specialised technology partner and formulation developer for its biopharmaceutical clients. Leukocare provides formulation development services based on its proprietary SPS® technology platform, resulting in outstanding stability of therapeutic proteins. Based on SPS®, Leukocare develops, for example, liquid dose forms of biopharmaceutical products with stability at high temperatures and a long shelf life. Its patented SPS® platform is characterised by specific and innovative combinations of established pharmaceutical excipients, which have already received regulatory approval.
The strategic goal of the alliance between the two companies is to take formulation development aspects into account at every step of the biopharmaceutical development and manufacturing. Working closely with the client, this will ensure from the outset that end products have a best-in-class formulation and dosage form. The alliance between Rentschler and Leukocare is a step towards improving and expanding the services sector in the biopharmaceutical branch.
Advisers to Rentschler Biotechnologie GmbH
GÖRG Partnerschaft von Rechtsanwälten mbB
Dr Bernt Paudtke, partner, Munich
Dr Oliver Spieker, partner, Munich
Michael Alber, associated partner, Berlin
Dr Christian Glauer, associate, Munich
Advisers to Leukocare AG
KLAKA Rechtsanwälte Partnerschaft mbB, Munich
Dr Stefan Eck, partner
honert + partner mbB, Munich
Dr Jürgen Honert, partner
Dr Philipp Kienzle, associate
